MTAP-결핍 및/또는 MTA 축적 암의 치료에 유용한 피페리딘-1-일-N-피리딘-3-일-2-옥소아세트아마이드 유도체
하기 화학식 (I)에 따른 화합물 및 이의 약제학적으로 허용 가능한 염, 및 이의 약제학적 조성물이 제공되되, 식 중 R1, R2, R3, R4, R6, R7, R8 및 n은 본 명세서에서 정의된 바와 같다. 본 발명의 화합물은 다양한 병태의 예방 및 치료에 유용한 것으로 상정된다. JPEGpct01845.jpg2874화학식 (I) Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical...
Saved in:
| Main Authors | , |
|---|---|
| Format | Patent |
| Language | Korean |
| Published |
27.06.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | 하기 화학식 (I)에 따른 화합물 및 이의 약제학적으로 허용 가능한 염, 및 이의 약제학적 조성물이 제공되되, 식 중 R1, R2, R3, R4, R6, R7, R8 및 n은 본 명세서에서 정의된 바와 같다. 본 발명의 화합물은 다양한 병태의 예방 및 치료에 유용한 것으로 상정된다. JPEGpct01845.jpg2874화학식 (I)
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. |
|---|---|
| AbstractList | 하기 화학식 (I)에 따른 화합물 및 이의 약제학적으로 허용 가능한 염, 및 이의 약제학적 조성물이 제공되되, 식 중 R1, R2, R3, R4, R6, R7, R8 및 n은 본 명세서에서 정의된 바와 같다. 본 발명의 화합물은 다양한 병태의 예방 및 치료에 유용한 것으로 상정된다. JPEGpct01845.jpg2874화학식 (I)
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. |
| Author | COTTRELL KEVIN M MAXWELL JOHN P |
| Author_xml | – fullname: COTTRELL KEVIN M – fullname: MAXWELL JOHN P |
| BookMark | eNrjYmDJy89L5WTo9A1xDNB9tWnD26m9Cq839Ou_njHhddcUBaCwwpttU98saFR4M3XKm7kzFN7snPF6cc-b6RMU3sxZ8GbWyrdT5yi8nbLnbd-M18vWvJ4yQ9dQ983cPbp-ukBBqIgxWMRI982MpW_aet5MbXnTsuNt1w4g4_Xyjjdzt7yePAdk2Ov-ljebtvAwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUknjvICMDI2MDA0sTQ0szR2PiVAEAFv1u-A |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | KR20230094196A |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_KR20230094196A3 |
| IEDL.DBID | EVB |
| IngestDate | Fri Aug 30 05:41:41 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | Korean |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_KR20230094196A3 |
| Notes | Application Number: KR20237006890 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230627&DB=EPODOC&CC=KR&NR=20230094196A |
| ParticipantIDs | epo_espacenet_KR20230094196A |
| PublicationCentury | 2000 |
| PublicationDate | 20230627 |
| PublicationDateYYYYMMDD | 2023-06-27 |
| PublicationDate_xml | – month: 06 year: 2023 text: 20230627 day: 27 |
| PublicationDecade | 2020 |
| PublicationYear | 2023 |
| RelatedCompanies | TANGO THERAPEUTICS, INC |
| RelatedCompanies_xml | – name: TANGO THERAPEUTICS, INC |
| Score | 3.431735 |
| Snippet | 하기 화학식 (I)에 따른 화합물 및 이의 약제학적으로 허용 가능한 염, 및 이의 약제학적 조성물이 제공되되, 식 중 R1, R2, R3, R4, R6, R7, R8 및 n은 본 명세서에서 정의된 바와 같다. 본 발명의 화합물은 다양한 병태의 예방 및 치료에 유용한 것으로 상정된다.... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | MTAP-결핍 및/또는 MTA 축적 암의 치료에 유용한 피페리딘-1-일-N-피리딘-3-일-2-옥소아세트아마이드 유도체 |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230627&DB=EPODOC&locale=&CC=KR&NR=20230094196A |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTZLS0xOMzTTTUlNNtI1SQVd85JsmaKbZmZkYJxonJaclgba7-zrZ-YRauIVYRrBxJAD2wsDPie0HHw4IjBHJQPzewm4vC5ADGK5gNdWFusnZQKF8u3dQmxd1KC9Y1B72shczcXJ1jXA38XfWc3Z2dY7SM0vCCIH7MoAE5wjMwMrsCFtDu62hTmB9qUUIFcqboIMbAFA8_JKhBiYsvOFGTidYXevCTNw-EKnvIFMaO4rFmHo9A1xDNB9tWnD26m9Cq839Ou_njHhddcUBaCwwpttU98saFR4M3XKm7kzFN7snPF6cc-b6RMU3sxZ8GbWyrdT5yi8nbLnbd-M18vWvJ4yA9ijezN3j66fLlAQKmIMFjHSfTNj6Zu2njdTW9607HjbtQPIeL28483cLa8nzwEZ9rq_5c2mLaIMym6uIc4eukA_xcODMN47CDkAjMUYWPLy81IlGBQM0oySzJISjRINLBNNkpIskpKSkhOTzA1TUhMNzFINUyQZZPCZJIVfWpqBC8QFLa0yMpdhYCkpKk2VBVbiJUly4LAHADgKxTA |
| link.rule.ids | 230,309,783,888,25577,76883 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMTZLS0xOMzTTTUlNNtI1SQVd85JsmaKbZmZkYJxonJaclgba7-zrZ-YRauIVYRrBxJAD2wsDPie0HHw4IjBHJQPzewm4vC5ADGK5gNdWFusnZQKF8u3dQmxd1KC9Y1B72shczcXJ1jXA38XfWc3Z2dY7SM0vCCIH7MoAE5wjMwMrsJFtAe4shTmB9qUUIFcqboIMbAFA8_JKhBiYsvOFGTidYXevCTNw-EKnvIFMaO4rFmHo9A1xDNB9tWnD26m9Cq839Ou_njHhddcUBaCwwpttU98saFR4M3XKm7kzFN7snPF6cc-b6RMU3sxZ8GbWyrdT5yi8nbLnbd-M18vWvJ4yA9ijezN3j66fLlAQKmIMFjHSfTNj6Zu2njdTW9607HjbtQPIeL28483cLa8nzwEZ9rq_5c2mLaIMym6uIc4eukA_xcODMN47CDkAjMUYWPLy81IlGBQM0oySzJISjRINLBNNkpIskpKSkhOTzA1TUhMNzFINUyQZZPCZJIVfWp6B0yPE1yfex9PPW5qBCyQFWmZlZC7DwFJSVJoqC6zQS5LkwPEAAKDHyCA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=MTAP-%EA%B2%B0%ED%95%8D+%EB%B0%8F%2F%EB%98%90%EB%8A%94+MTA+%EC%B6%95%EC%A0%81+%EC%95%94%EC%9D%98+%EC%B9%98%EB%A3%8C%EC%97%90+%EC%9C%A0%EC%9A%A9%ED%95%9C+%ED%94%BC%ED%8E%98%EB%A6%AC%EB%94%98-1-%EC%9D%BC-N-%ED%94%BC%EB%A6%AC%EB%94%98-3-%EC%9D%BC-2-%EC%98%A5%EC%86%8C%EC%95%84%EC%84%B8%ED%8A%B8%EC%95%84%EB%A7%88%EC%9D%B4%EB%93%9C+%EC%9C%A0%EB%8F%84%EC%B2%B4&rft.inventor=COTTRELL+KEVIN+M&rft.inventor=MAXWELL+JOHN+P&rft.date=2023-06-27&rft.externalDBID=A&rft.externalDocID=KR20230094196A |